EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex

Francesco Nappi iD

Pathogens · 2026

DOI: 10.3390/pathogens15040449 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2026. Verfasst von Francesco Nappi. Beteiligte Einrichtung: Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Carbapenems, Acinetobacter Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease Control and Prevention (CDC) identified carbapenem-resistant Acinetobacter baumannii (CRAB) infections as a threat to human health. The World Health Organization (WHO) has classified it as a top priority for research. In 2023, the US FDA approved sulbactam–durlobactam for treating certain A. baumannii infections. As of 2024, this combination is designated as the preferred treatment strategy by the Infectious Diseases Society of America (IDSA) for infections due to carbapenem-resistant A. baumannii. In this therapeutic review, the preclinical and clinical data relevant to this regulatory decision were analyzed. This in-depth analysis will provide a comprehensive overview of the complex subject matter. It should be observed that carbapenem-based combination therapy is indicated for carbapenem-resistant A. baumannii.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulbactamAcinetobacter baumanniiCarbapenemsAcinetobacter InfectionsAnti-Bacterial AgentsAzabicyclo CompoundsAcinetobacter calcoaceticusHumansDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Acinetobacter baumannii infectioncarbapenem-resistant Acinetobacter baumanniihospital-acquired bacterial pneumoniamultidrug-resistant Acinetobacter baumannii–calcoaceticus complexsulbactam–durlobactamventilator-associated bacterial pneumonia

Substanzen

SulbactamCarbapenemsAnti-Bacterial AgentsdurlobactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France.

ORCID-Profile: Francesco Nappi

Zitieren

APA

Nappi, F. (2026). Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex. Pathogens. https://doi.org/10.3390/pathogens15040449

Vancouver

Nappi F. Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex. Pathogens. 2026. doi:10.3390/pathogens15040449

BibTeX
@article{Nappi2026,
  author = {Nappi, Francesco},
  title = {Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15040449}
}
Kostenlos starten →